Startup profile · funding coverage
Stipple Bio funding, valuation and investors
Precision oncology antibodies from epitope-level tumor targeting via Pointillist platform.
Keep track of Stipple Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$100M · April 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$100M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Investors in latest funding
Lead: Andreessen Horowitz , RA Capital
Overview
Stipple Bio discovers tumor-specific epitopes using its Pointillist platform and develops precision oncology antibodies with wider therapeutic windows for solid tumors. The approach targets epitope-level specificity rather than whole-protein markers alone. In April 2026, the company announced an oversubscribed $100M Series A co-led by Andreessen Horowitz Bio + Health, RA Capital, and Nextech Invest, with lead asset STP-100 entering the clinic. Stipple operates in the crowded immuno-oncology space but differentiates on granular epitope mapping for solid tumor selectivity.
Why Stipple Bio is interesting
Stipple maps tumor-specific epitopes beyond protein targets — a16z Bio+Health co-led oversubscribed $100M Series A as STP-100 enters clinic.
Product & use cases
Stipple's Pointillist platform identifies tumor-specific epitopes and feeds antibody discovery programs aimed at solid tumors with improved selectivity versus healthy tissue.
- Solid tumor antibody programs with epitope-level targeting
- Biopharma partnerships on precision oncology pipelines
- Clinical development of lead asset STP-100
Key facts
- Series A (Apr 2026): $100M co-led by a16z Bio+Health, RA Capital, Nextech Invest (GlobeNewswire)
- Pointillist epitope-discovery platform for solid tumors
- Lead asset STP-100 entering clinic (company press)
- Precision oncology antibody focus
Funding history (newest first)
Series A
2026-04 $100M- Andreessen Horowitz (lead)
- RA Capital (lead)
Source: https://www.globenewswire.com/news-release/2026/04/stipple-bio-series-a
Investors in our directory
Funds linked from Stipple Bio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Epitope-resolution discovery may unlock targets missed by conventional protein-level screens — thesis unproven clinically but differentiated scientifically.
Oncology biotech is capital-intensive with high clinical failure rates. Stipple's $100M Series A buys runway to prove STP-100; science risk remains typical of pre/early-clinical IO.
-
Genmab / precision IO peers adjacent
Established antibody oncology franchises.
-
AbCellera adjacent
Antibody discovery platform partner model.
-
Traditional ADC developers adjacent
Different modality; compete for solid tumor budgets.
Notable stories
- Stipple's $100M Series A in 2026 signals investor appetite for solid-tumor selectivity plays even as many IO programs fail — epitope-level targeting is the differentiated scientific bet (GlobeNewswire).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Stipple Bio's financing or category context.
FAQs about Stipple Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.